Orum Therapeutics Closes $84 Million Series B Financing to Advance Novel Targeted Protein Degrader Payloads into Clinical Trials for Cancer

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/35NHh34
via IFTTT